Morgan Stanley analyst Joseph Moore upgrades NVIDIA (NASDAQ:NVDA) from Equal-Weight to Overweight and raises the price target from $255 to $304.
Chemomab Wins New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent
